{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:46:07Z","timestamp":1769856367321,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40123-021-00342-5","type":"journal-article","created":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T16:02:55Z","timestamp":1618070575000},"page":"231-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion"],"prefix":"10.1007","volume":"10","author":[{"given":"Konstantinos","family":"Balaskas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried M.","family":"Amoaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Cudrnak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise M.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Groppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quresh","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Severn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Vardarinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yit C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,10]]},"reference":[{"key":"342_CR1","unstructured":"NICE. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. 2008. www.nice.org.uk\/guidance\/ta155. Accessed 2020."},{"issue":"5","key":"342_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/bjophthalmol-2011-301109","volume":"96","author":"CG Owen","year":"2012","unstructured":"Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96(5):752\u20136.","journal-title":"Br J Ophthalmol"},{"key":"342_CR3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.2147\/OPTH.S174560","volume":"12","author":"W Amoaku","year":"2018","unstructured":"Amoaku W, Balaskas K, Cudrnak T, et al. Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group. Clin Ophthalmol. 2018;12:1731\u201340.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"342_CR4","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41433-020-0864-6","volume":"34","author":"F Rahman","year":"2020","unstructured":"Rahman F, Zekite A, Bunce C, Jayaram H, Flanagan D. Recent trends in vision impairment certifications in England and Wales. Eye (Lond). 2020;34(7):1271\u20138.","journal-title":"Eye (Lond)"},{"key":"342_CR5","unstructured":"Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119(2):198\u2013207."},{"issue":"14","key":"342_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"342_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","volume":"33","author":"RP Gale","year":"2019","unstructured":"Gale RP, Mahmood S, Devonport H, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye (Lond). 2019;33(Suppl 1):1\u201321.","journal-title":"Eye (Lond)"},{"key":"342_CR8","unstructured":"NICE. NG82. Age-related macular degeneration. 2018. www.nice.org.uk\/guidance\/ng82. Accessed 2020."},{"issue":"4","key":"342_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris 3rd","year":"2013","unstructured":"Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120(4):844\u201351.","journal-title":"Ophthalmology"},{"issue":"2","key":"342_CR10","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1111\/aos.13519","volume":"96","author":"E Cobos","year":"2018","unstructured":"Cobos E, Recalde S, Anter J, et al. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration. Acta Ophthalmol. 2018;96(2):e201\u201312.","journal-title":"Acta Ophthalmol"},{"key":"342_CR11","first-page":"5","volume":"2020","author":"U Chakravarthy","year":"2020","unstructured":"Chakravarthy U, Pillai N, Syntosi A, Barclay L, Best C, Sagkriotis A. Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration. Eye (Lond). 2020;2020:5.","journal-title":"Eye (Lond)."},{"issue":"5","key":"342_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL, et al. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019;126(5):723\u201334.","journal-title":"Ophthalmology"},{"issue":"6","key":"342_CR13","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2018;125(6):878\u201386.","journal-title":"Ophthalmology"},{"key":"342_CR14","unstructured":"Evans EN, Chakravarthy U, Reeves B. Associations between variation in retinal thickness and visual function. In: Paper presented at: ARVO2019; Vancouver; 2018."},{"issue":"2","key":"342_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","volume":"145","author":"CD Regillo","year":"2008","unstructured":"Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239\u201348.","journal-title":"Am J Ophthalmol"},{"key":"342_CR16","first-page":"73","volume":"2013","author":"D Brown","year":"2013","unstructured":"Brown D. Correlation between changes in OCT and visual acuity in the management of neovascular AMD. Retina Today. 2013;2013:73\u20135.","journal-title":"Retina Today."},{"issue":"1","key":"342_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/IAE.0b013e318263cedf","volume":"33","author":"DM Brown","year":"2013","unstructured":"Brown DM, Tuomi L, Shapiro H, Pier Study G. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina. 2013;33(1):23\u201334.","journal-title":"Retina"},{"issue":"7","key":"342_CR18","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"CATT Research G, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388\u201398.","journal-title":"Ophthalmology"},{"issue":"7","key":"342_CR19","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"IS Investigators","year":"2012","unstructured":"Investigators IS, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399\u2013411.","journal-title":"Ophthalmology"},{"issue":"11","key":"342_CR20","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","volume":"120","author":"L Kodjikian","year":"2013","unstructured":"Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120(11):2300\u20139.","journal-title":"Ophthalmology"},{"issue":"5","key":"342_CR21","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046\u201356.","journal-title":"Ophthalmology"},{"issue":"1","key":"342_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146\u201352.","journal-title":"Ophthalmology"},{"issue":"12","key":"342_CR23","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.ophtha.2015.08.014","volume":"122","author":"G Richard","year":"2015","unstructured":"Richard G, Mones J, Wolf S, et al. Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology. 2015;122(12):2497\u2013503.","journal-title":"Ophthalmology"},{"issue":"12","key":"342_CR24","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122(12):2514\u201322.","journal-title":"Ophthalmology"},{"issue":"6","key":"342_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","volume":"126","author":"PJ Kertes","year":"2019","unstructured":"Kertes PJ, Galic IJ, Greve M, et al. Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized canadian treat-and-extend analysis trial with ranibizumab study. Ophthalmology. 2019;126(6):841\u20138.","journal-title":"Ophthalmology"},{"issue":"4","key":"342_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","volume":"137","author":"MC Gillies","year":"2019","unstructured":"Gillies MC, Hunyor AP, Arnold JJ, et al. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2019;137(4):372\u20139.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"342_CR27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-Week Findings from ALTAIR:  a randomized controlled trial. Adv Ther. 2020;37(3):1173\u201387.","journal-title":"Adv Ther"},{"issue":"6","key":"342_CR28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","volume":"121","author":"C Simader","year":"2014","unstructured":"Simader C, Ritter M, Bolz M, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121(6):1237\u201345.","journal-title":"Ophthalmology"},{"issue":"20","key":"342_CR29","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908.","journal-title":"N Engl J Med."},{"issue":"7","key":"342_CR30","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388\u201398.","journal-title":"Ophthalmology"},{"issue":"4","key":"342_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","volume":"123","author":"S Sharma","year":"2016","unstructured":"Sharma S, Toth CA, Daniel E, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(4):865\u201375.","journal-title":"Ophthalmology"},{"issue":"9900","key":"342_CR32","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258\u201367.","journal-title":"Lancet"},{"issue":"7","key":"342_CR33","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/IAE.0000000000000902","volume":"36","author":"SS Wickremasinghe","year":"2016","unstructured":"Wickremasinghe SS, Janakan V, Sandhu SS, Amirul-Islam FM, Abedi F, Guymer RH. Implication of recurrent or retained fluid on optical coherence tomography for visual acuity during active treatment of neovascular age-related macular degeneration with a treat and extend protocol. Retina. 2016;36(7):1331\u20139.","journal-title":"Retina"},{"issue":"9","key":"342_CR34","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","volume":"120","author":"GJ Jaffe","year":"2013","unstructured":"Jaffe GJ, Martin DF, Toth CA, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120(9):1860\u201370.","journal-title":"Ophthalmology"},{"issue":"2","key":"342_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/eye.2015.217","volume":"30","author":"V Chong","year":"2016","unstructured":"Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond). 2016;30(2):270\u201386.","journal-title":"Eye (Lond)"},{"issue":"2","key":"342_CR36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"342_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12886-017-0451-1","volume":"17","author":"A Vardarinos","year":"2017","unstructured":"Vardarinos A, Gupta N, Janjua R, Iron A, Empeslidis T, Tsaousis KT. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting. BMC Ophthalmol. 2017;17(1):58.","journal-title":"BMC Ophthalmol"},{"key":"342_CR38","unstructured":"AAO. American Academy of Ophthalmology Retina\/Vitreo Panel. Preferred practice pattern guidelines. age-related macular degeneration. 2015. www.aao.org\/ppp. Accessed 2020."},{"key":"342_CR39","unstructured":"RCOphth. Age-related macular degeneration: guidelines for management. 2013. http:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2014\/12\/2013-SCI-318-RCOphth-AMD-Guidelines-Sept-2013-FINAL-2.pdf. Accessed 2020."},{"issue":"9","key":"342_CR40","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144\u201367.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"342_CR41","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/eye.2014.214","volume":"28","author":"MM Castillo","year":"2014","unstructured":"Castillo MM, Mowatt G, Lois N, et al. Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review. Eye (Lond). 2014;28(12):1399\u2013406.","journal-title":"Eye (Lond)"},{"issue":"2","key":"342_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ophtha.2014.07.055","volume":"122","author":"MM Castillo","year":"2015","unstructured":"Castillo MM, Mowatt G, Elders A, et al. Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review. Ophthalmology. 2015;122(2):399\u2013406.","journal-title":"Ophthalmology"},{"key":"342_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajo.2019.06.026","volume":"208","author":"TD Wibbelsman","year":"2019","unstructured":"Wibbelsman TD, Pandit RR, Xu D, et al. Trends in retina specialist imaging utilization from 2012 to 2016 in the United States medicare fee-for-service population. Am J Ophthalmol. 2019;208:12\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"342_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43\u201358.","journal-title":"Am J Ophthalmol."},{"issue":"3","key":"342_CR45","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00417-014-2585-7","volume":"252","author":"F Cruz-Gonzalez","year":"2014","unstructured":"Cruz-Gonzalez F, Cabrillo-Estevez L, Lopez-Valverde G, Cieza-Borrella C, Hernandez-Galilea E, Gonzalez-Sarmiento R. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD. Graefes Arch Clin Exp Ophthalmol. 2014;252(3):469\u201375.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"342_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1167\/iovs.16-19969","volume":"57","author":"PJ Rosenfeld","year":"2016","unstructured":"Rosenfeld PJ. Optical coherence tomography and the development of antiangiogenic therapies in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016;57(9):14\u201326.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"3","key":"342_CR47","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/opo.12613","volume":"39","author":"A Jindal","year":"2019","unstructured":"Jindal A, Ctori I, Fidalgo B, Dabasia P, Balaskas K, Lawrenson JG. Impact of optical coherence tomography on diagnostic decision-making by UK community optometrists: a clinical vignette study. Ophthalmic Physiol Opt. 2019;39(3):205\u201315.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"7","key":"342_CR48","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/IAE.0000000000000483","volume":"35","author":"CA Toth","year":"2015","unstructured":"Toth CA, Decroos FC, Ying GS, et al. Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the comparison of age-related macular degeneration treatments trials. Retina. 2015;35(7):1303\u201314.","journal-title":"Retina"},{"key":"342_CR49","first-page":"100906","volume":"2020","author":"PS Mettu","year":"2020","unstructured":"Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2020;2020:100906.","journal-title":"Prog Retin Eye Res."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-021-00342-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-021-00342-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-021-00342-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T09:31:14Z","timestamp":1675157474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-021-00342-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,10]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1007\/s40123-021-00342-5","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,10]]},"assertion":[{"value":"25 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}